Joachim N. Nilsson

Simplified dosimetry for kidneys and tumors in 177Lu-labeled peptide receptor radionuclide therapy

Oscar Ardenfors, Joachim N. Nilsson, Daniel E. Thor et al. · EJNMMI Physics · 2022 · 36 citations · Full text

Medicine, Nuclear Medicine, Radiology +17

A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-Risk Neuroblastoma–LuDO-N

Fredrik Sundquist, Kleopatra Georgantzi, Kirsten Brunsvig Jarvis et al. · Frontiers in Pediatrics · 2022 · 31 citations · Full text

Medicine, Nuclear Medicine, Radiation Oncology +17

Pre-Therapeutic Measurements of Iodine Avidity in Papillary and Poorly Differentiated Thyroid Cancer Reveal Associations with Thyroglobulin Expression, Histological Variants and Ki-67 Index

Joachim N. Nilsson, Jonathan Siikanen, Christel Hedman et al. · Cancers · 2021 · 21 citations · Full text

Medicine, Nuclear Medicine, Pathology +17

Iodine avidity in papillary and poorly differentiated thyroid cancer is predicted by immunohistochemical and molecular work-up

Joachim N. Nilsson, Jonathan Siikanen, Vincenzo Condello et al. · European Thyroid Journal · 2023 · 16 citations · Full text

Medicine, Endocrinology, Oncology +17

Risk of treatment-altering haematological toxicity and its dependence on bone marrow doses in peptide receptor radionuclide therapy

M. Persson, Cécilia Hindorf, Oscar Ardenfors et al. · EJNMMI Research · 2024 · 14 citations · Full text

Medicine, Hematology, Nuclear Medicine +17